Jacobson Pharma Corporation Limited, through its subsidiaries, develops, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including gastrointestinal disorders, cardiovascular conditions, inflammatory and autoimmune diseases, multiple myeloma treatment, oncology, breast cancer therapy, central nervous system, respiratory, oral antidiabetics, musculo-skeletal, genito-urinary, anti-infectives, endocrine and metabolic, dermatological, and anti-allergics. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines; treasury services; and management services. In addition, the company engages in the manufacture, sale, trading of pharmaceutical products; property holding activities; holding of pharmaceutical licenses; trading of medical supplies; sales of healthcare and herbal products; and procurement of packaging materials. It sells its products to hospitals and clinics, and registered pharmacies, as well as to private doctors and retail outlets, and trading companies. Jacobson Pharma Corporation Limited was incorporated in 2016 and is headquartered in Kwun Tong, Hong Kong.